Current data indicate AFP demonstrates suboptimal sensitivity (∼60 %) and specificity (∼80 %), with particular shortcomings in detecting early-stage HCC and distinguishing malignant lesions from benign liver conditions such as cirrhosis or chronic hepatitis [43]. The gene discussed is AFP; the disease is hepatocellular carcinoma.